Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04458610 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Rituximab
DRUG: Zanubrutinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]